Free Trial

Taysha Gene Therapies (TSHA) Competitors

Taysha Gene Therapies logo
$2.65 +0.06 (+2.32%)
Closing price 04:00 PM Eastern
Extended Trading
$2.66 +0.00 (+0.19%)
As of 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TSHA vs. HHH, KNSA, TWST, CNTA, BEAM, CGON, DNLI, HRMY, IRON, and MESO

Should you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Howard Hughes (HHH), Kiniksa Pharmaceuticals International (KNSA), Twist Bioscience (TWST), Centessa Pharmaceuticals (CNTA), Beam Therapeutics (BEAM), CG Oncology (CGON), Denali Therapeutics (DNLI), Harmony Biosciences (HRMY), Disc Medicine (IRON), and Mesoblast (MESO).

Taysha Gene Therapies vs. Its Competitors

Taysha Gene Therapies (NASDAQ:TSHA) and Howard Hughes (NYSE:HHH) are related companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Taysha Gene Therapies currently has a consensus price target of $8.17, indicating a potential upside of 208.18%. Howard Hughes has a consensus price target of $80.33, indicating a potential upside of 15.15%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Taysha Gene Therapies is more favorable than Howard Hughes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Taysha Gene Therapies
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Howard Hughes
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 93.8% of Howard Hughes shares are owned by institutional investors. 3.8% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 33.0% of Howard Hughes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Taysha Gene Therapies has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Howard Hughes has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.

Howard Hughes has a net margin of 14.27% compared to Taysha Gene Therapies' net margin of -1,201.08%. Howard Hughes' return on equity of 10.21% beat Taysha Gene Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Taysha Gene Therapies-1,201.08% -104.93% -50.09%
Howard Hughes 14.27%10.21%3.08%

In the previous week, Howard Hughes had 3 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 4 mentions for Howard Hughes and 1 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 1.87 beat Howard Hughes' score of 1.69 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company Overall Sentiment
Taysha Gene Therapies Very Positive
Howard Hughes Very Positive

Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taysha Gene Therapies$8.33M68.29-$89.30M-$0.34-7.79
Howard Hughes$1.75B2.01$200.55M$5.2113.39

Summary

Howard Hughes beats Taysha Gene Therapies on 11 of the 16 factors compared between the two stocks.

Get Taysha Gene Therapies News Delivered to You Automatically

Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TSHA vs. The Competition

MetricTaysha Gene TherapiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$555.97M$3.87B$5.70B$9.51B
Dividend YieldN/A1.17%4.69%4.01%
P/E Ratio-7.794.4621.1920.14
Price / Sales68.2911.99461.30104.37
Price / CashN/A6.4836.2258.56
Price / Book7.572.798.665.87
Net Income-$89.30M-$109.62M$3.25B$258.55M
7 Day Performance3.11%5.55%4.20%2.23%
1 Month Performance8.61%11.53%10.82%12.76%
1 Year Performance16.74%23.43%34.70%19.36%

Taysha Gene Therapies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TSHA
Taysha Gene Therapies
4.2565 of 5 stars
$2.65
+2.3%
$8.17
+208.2%
+15.6%$555.97M$8.33M-7.79180Positive News
HHH
Howard Hughes
2.9072 of 5 stars
$68.93
+0.2%
$80.33
+16.5%
+1.1%$3.46B$1.75B11.79608Positive News
KNSA
Kiniksa Pharmaceuticals International
3.4621 of 5 stars
$28.42
-2.1%
$39.33
+38.4%
+6.7%$2.12B$423.24M-113.68220News Coverage
TWST
Twist Bioscience
4.3708 of 5 stars
$34.77
-1.1%
$50.40
+45.0%
-37.4%$2.11B$312.97M-10.70990Positive News
CNTA
Centessa Pharmaceuticals
3.3263 of 5 stars
$16.06
+2.4%
$28.10
+75.0%
+51.2%$2.10B$6.85M-8.87200Insider Trade
BEAM
Beam Therapeutics
2.2257 of 5 stars
$21.03
+1.3%
$48.75
+131.8%
-29.7%$2.09B$63.52M-4.56510Analyst Revision
CGON
CG Oncology
2.2411 of 5 stars
$26.90
+0.6%
$55.30
+105.6%
-21.3%$2.04B$1.14M0.0061
DNLI
Denali Therapeutics
4.2668 of 5 stars
$13.83
-1.2%
$33.71
+143.8%
-39.4%$2.03B$330.53M-5.18430News Coverage
Upcoming Earnings
HRMY
Harmony Biosciences
4.7998 of 5 stars
$35.25
+0.1%
$51.00
+44.7%
+11.9%$2.02B$714.73M13.45200Positive News
Analyst Revision
IRON
Disc Medicine
3.3645 of 5 stars
$59.38
+2.8%
$95.73
+61.2%
+36.0%$2.00BN/A-15.1530
MESO
Mesoblast
1.4489 of 5 stars
$14.65
-6.2%
$18.00
+22.9%
+113.6%$2.00B$5.90M0.0080Upcoming Earnings
Gap Down

Related Companies and Tools


This page (NASDAQ:TSHA) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners